title: Trends in biopharmaceutical IPOS: 1996-2005.
abstract: This study examines the stock market reaction and other financial aspects of all biopharmaceutical firms that had an initial public offering (IPO) between 1996 and 2005. Overall, increases in stock price at the close of the first day averaged 20.9 percent while the stock price of those firms that went public and survived until the end of 2005 stock price increased by only 7.7 percent on average. Sixty-nine percent of the firms that went public during this period were still trading at the end of 2005, with the majority of those de-listed being acquired or merged. Three-fourths of all biopharmaceutical IPOs had venture capital investors. Venture capitalists owned 47.4 percent of all common stock outstanding prior to the IPO on average.
authors.affiliation: Department of Management, Walker College of Business, Appalachian State University, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Williams
authors.forename: Carlton C
authors.initials: CC
authors.lastname: Young
mesh_terms: D000288:Administrative Personnel / Q000191:economics; D001709:Biotechnology / Q000191:economics* / Q000639:trends; D002202:Capital Financing / Q000706:statistics & numerical data / Q000639:trends*; D003625:Data Collection; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D004649:Employee Incentive Plans; D016520:Entrepreneurship / Q000639:trends*; D019981:Health Care Sector / Q000706:statistics & numerical data / Q000639:trends*; D006801:Humans; D007449:Investments / Q000145:classification / Q000706:statistics & numerical data / Q000639:trends*; D017149:Private Sector / Q000191:economics*; D012456:Salaries and Fringe Benefits; D014481:United States